| Chronic Lymphocytic Leukemia
Brukinsa vs Bendeka
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Brukinsa vs Bendeka with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBendeka has a higher rate of injection site reactions vs Brukinsa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bendeka but not Brukinsa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brukinsa
Bendeka
At A Glance
Oral
Once or twice daily
BTK inhibitor
IV infusion
Every 3-4 weeks
Alkylating agent
Indications
- Mantle cell lymphoma
- Waldenstrom Macroglobulinemia
- Marginal Zone B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoma, Follicular
- Chronic Lymphocytic Leukemia
- Indolent B-Cell Non-Hodgkin Lymphoma
Dosing
Mantle cell lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 160 mg orally twice daily or 320 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Lymphoma, Follicular 160 mg orally twice daily in combination with obinutuzumab, with or without food, until disease progression or unacceptable toxicity.
Chronic Lymphocytic Leukemia 100 mg/m2 IV over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Indolent B-Cell Non-Hodgkin Lymphoma 120 mg/m2 IV over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
Contraindications
—
- Known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol
Adverse Reactions
Most common (>=30%) Neutrophil count decreased, platelet count decreased, upper respiratory tract infection, hemorrhage, musculoskeletal pain
Serious Hemorrhage, pneumonia, cytopenias, second primary malignancies, cardiac arrhythmias, hepatotoxicity including drug-induced liver injury
Postmarketing Drug-induced liver injury
Most common (>=30%) Nausea, fatigue, vomiting, diarrhea, pyrexia
Serious Febrile neutropenia, pneumonia, acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, myelodysplastic syndrome
Postmarketing Pancytopenia, atrial fibrillation, congestive heart failure, myocardial infarction, anaphylaxis, progressive multifocal leukoencephalopathy, nephrogenic diabetes insipidus, pneumonitis, DRESS, non-melanoma skin cancer, Stevens-Johnson syndrome, toxic epidermal necrolysis
Pharmacology
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity and thereby blocking B-cell proliferation, trafficking, chemotaxis, and adhesion pathways driven by B-cell antigen receptor and cytokine receptor signaling.
Bendamustine is a bifunctional mechlorethamine derivative containing a benzimidazole ring that forms electrophilic alkyl groups, which create covalent interstrand DNA crosslinks leading to cell death via multiple pathways; it is active against both quiescent and dividing cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brukinsa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Bendeka
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Brukinsa
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (4/8)
Bendeka
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Brukinsa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Bendeka
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brukinsa.
No savings programs available for Bendeka.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrukinsaView full Brukinsa profile
BendekaView full Bendeka profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.